Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK117 + AK112 with chemotherapy as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer
CTR20220115Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab, ivonescimab in triple-negative breast cancer (TNBC), sponsored by Akeso, Inc.. Started Mar 2022; status: active.
02
Drugs
ligufalimabivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20220115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220115.